The goal of this project is to determine relationships among the clinical, cognitive, imaging, genetic and biochemical biomarker characteristics of the entire spectrum of Alzheimer's disease (AD), as pathology evolves from normal aging to very mild symptoms, to mild cognitive impairment (MCI), to dementia. ADNl will inform the neuroscience of AD, identify diagnostic and prognostic markers, identify outcome measures that can be used in clinical trials, and help develop the most effective clinical trial scenarios. ADNI2 continues the currently funded AD Neuroimaging Initiative (ADNI1), a public/private collaboration between academia and industry to study biomarkers of AD as well as a recently funded Grand Opportunities grant that supplements ADNl goals and activities (GO). New aspects of ADNl include enrolling subjects with early MCI (EMCI), F18 amyloid imaging, and obtaining all clinical/cognitive, lumbar puncture CSF and plasma biomarker, and MRI/PET data on all subjects. The goals of this ADNl renewal will be accomplished by: 1) continuing annual clinical/cognitive/MRI follow up of the 476 normal controls and late MCI (LMCI) subjects previously enrolled in ADNI1;2) following the 200 EMCI subjects enrolled in the GO ADNl grant;3) additional enrollment of new healthy controls (n=150), EMCI (n=100 which adds to the 200 subjects enrolled in GO), LMCI (n=150), and AD (n=150) subjects;4) performance of F18 amyloid PET (using F18 AV-45 from AVID, Inc.) on all new subjects enrolled in ADNI2, together with FDG PET, and to obtain a 2nd F18 amyloid PET on all remaining ADNI1, GO, and ADNI2 subjects 2 years after the baseline scan;5) continue to obtain annual clinical/cognitive/blood draw/lumbar puncture for CSF, and MRI on all subjects. All collected data will be processed and analyzed by ADNl investigators including the Biostatistical Core, and made available to all qualified scientists in the world who request a password, without embargo. Hypotheses developed from current ADNl data will be replicated and new hypotheses tested, especially concerning EMCI and F18 amyloid imaging. ADNl spawned large multisite projects in other countries. No other large multisite study in the world addresses these complex issues with the sample size and statistical power of this application.

Public Health Relevance

Alzheimer's disease (AD) causes cognitive impairment and dementia in millions of Americans and costs more than $100 billion/year in the USA. This ADNl project will provide new information which will greatly facilitate design of clinical treatment trials and will help develop new diagnostic techniques which identify AD at an early stage, ultimately leading to effective treatment and prevention of AD. REVIEW OF THE OVERALL PROGRAM

Agency
National Institute of Health (NIH)
Type
Research Project--Cooperative Agreements (U01)
Project #
3U01AG024904-09S2
Application #
8824600
Study Section
Special Emphasis Panel (ZAG1)
Program Officer
Ryan, Laurie M
Project Start
Project End
Budget Start
Budget End
Support Year
9
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Northern California Institute Research & Education
Department
Type
DUNS #
City
San Francisco
State
CA
Country
United States
Zip Code
94121
Teng, Edmond; Chow, Nicole; Hwang, Kristy S et al. (2015) Low plasma ApoE levels are associated with smaller hippocampal size in the Alzheimer's disease neuroimaging initiative cohort. Dement Geriatr Cogn Disord 39:154-66
Ramanan, V K; Nho, K; Shen, L et al. (2015) FASTKD2 is associated with memory and hippocampal structure in older adults. Mol Psychiatry 20:1197-204
Rueda, Alicia D; Lau, Karen M; Saito, Naomi et al. (2015) Self-rated and informant-rated everyday function in comparison to objective markers of Alzheimer's disease. Alzheimers Dement 11:1080-9
Caroli, Anna; Prestia, Annapaola; Wade, Sara et al. (2015) Alzheimer Disease Biomarkers as Outcome Measures for Clinical Trials in MCI. Alzheimer Dis Assoc Disord 29:101-9
Varon, Daniel; Barker, Warren; Loewenstein, David et al. (2015) Visual rating and volumetric measurement of medial temporal atrophy in the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort: baseline diagnosis and the prediction of MCI outcome. Int J Geriatr Psychiatry 30:192-200
Mah, Linda; Binns, Malcolm A; Steffens, David C et al. (2015) Anxiety symptoms in amnestic mild cognitive impairment are associated with medial temporal atrophy and predict conversion to Alzheimer disease. Am J Geriatr Psychiatry 23:466-76
Insel, Philip S; Mattsson, Niklas; Donohue, Michael C et al. (2015) The transitional association between ?-amyloid pathology and regional brain atrophy. Alzheimers Dement 11:1171-9
Bertens, Daniela; Knol, Dirk L; Scheltens, Philip et al. (2015) Temporal evolution of biomarkers and cognitive markers in the asymptomatic, MCI, and dementia stage of Alzheimer's disease. Alzheimers Dement 11:511-22
Retico, Alessandra; Bosco, Paolo; Cerello, Piergiorgio et al. (2015) Predictive Models Based on Support Vector Machines: Whole-Brain versus Regional Analysis of Structural MRI in the Alzheimer's Disease. J Neuroimaging 25:552-63
Leung, Kelvin K; Malone, Ian M; Ourselin, Sebastien et al. (2015) Effects of changing from non-accelerated to accelerated MRI for follow-up in brain atrophy measurement. Neuroimage 107:46-53

Showing the most recent 10 out of 601 publications